Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK)
Semarang, ID
PT Industri Jamu dan Farmasi Sido Muncul Tbk is an Indonesian enterprise specializing in the production and distribution of herbal remedies, cosmetics, and health-focused food and beverage items. Its operations are divided into three primary segments: Herbal Medicine and Supplements, Food and Beverage, and Pharmacy. The company offers a comprehensive range of both ethical (prescription) and over-the-counter products, addressing a vast array of health concerns such as pain management, immune system support, cardiovascular health, digestive wellness, skin conditions, and various other specific ailments. Beyond its core activities, Sido Muncul also engages in commercial ventures, land transportation, wastewater treatment, plantation management, and printing services. Established in 1940, the company is headquartered in Semarang, Indonesia, and operates as a subsidiary of PT Hotel Candi Baru.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.72% | -7.50% | -13.79% | -16.23% | -21.42% | -17.78% | -17.78% | -42.71% | -41.90% | +73.74% | +27.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | -1 |
| Buy | 4 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.1% Q1'26: -18.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+6.0% Q1'26: -35.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+30.5% Q1'26: +60.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+37.3% ★ Q1'26: +26.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+44.7% ★ Q1'26: +21.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.9% ★ Q1'26: -2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 8 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 7 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.22T
est: 2.25T (-1.2%)
|
2.56T
est: 2.53T (+1.3%)
|
2.57T
est: 2.53T (+1.9%)
|
2.76T
est: 2.73T (+1.1%)
|
3.07T
est: 3.03T (+1.4%)
|
3.34T
est: 3.29T (+1.3%)
|
4.02T
est: 3.96T (+1.5%)
|
3.87T
est: 3.78T (+2.2%)
|
3.57T
est: 3.81T (-6.4%)
|
3.92T
est: 3.83T (+2.3%)
|
4.08T
est: 4.04T (+0.9%)
|
4.22T
4.07T – 4.38T
+4.3% YoY
|
4.46T
4.23T – 4.67T
+5.8% YoY
|
4.77T
4.74T – 4.81T
+7.0% YoY
|
| EBITDA |
576.28B
est: 882.57B (-34.7%)
|
675.06B
est: 993.82B (-32.1%)
|
743.01B
est: 993.04B (-25.2%)
|
929.98B
est: 1.07T (-13.5%)
|
1.16T
est: 1.19T (-2.4%)
|
1.30T
est: 1.29T (+0.2%)
|
1.71T
est: 1.56T (+9.7%)
|
1.52T
est: 1.49T (+2.0%)
|
1.32T
est: 1.51T (-12.2%)
|
1.52T
est: 1.52T (+0.3%)
|
1.65T
est: 1.60T (+2.9%)
|
1.67T
1.61T – 1.73T
+4.3% YoY
|
1.77T
1.68T – 1.85T
+5.8% YoY
|
1.89T
1.88T – 1.90T
+7.0% YoY
|
| EBIT |
478.82B
est: 833.60B (-42.6%)
|
582.40B
est: 938.69B (-38.0%)
|
641.06B
est: 937.94B (-31.7%)
|
816.30B
est: 1.01T (-19.6%)
|
1.07T
est: 1.12T (-4.4%)
|
1.20T
est: 1.22T (-1.9%)
|
1.61T
est: 1.47T (+9.7%)
|
1.42T
est: 1.40T (+1.2%)
|
1.22T
est: 1.42T (-14.4%)
|
1.51T
est: 1.43T (+5.5%)
|
1.52T
est: 1.51T (+0.7%)
|
1.58T
1.52T – 1.64T
+4.3% YoY
|
1.67T
1.58T – 1.75T
+5.8% YoY
|
1.78T
1.77T – 1.80T
+7.0% YoY
|
| Net Income |
437.47B
est: 423.52B (+3.3%)
|
480.53B
est: 476.36B (+0.9%)
|
533.80B
est: 521.02B (+2.5%)
|
663.85B
est: 658.78B (+0.8%)
|
807.69B
est: 800.40B (+0.9%)
|
934.02B
est: 916.67B (+1.9%)
|
1.26T
est: 1.18T (+6.6%)
|
1.10T
est: 1.07T (+3.4%)
|
950.65B
est: 1.11T (-14.4%)
|
1.17T
est: 1.16T (+0.7%)
|
1.23T
est: 1.21T (+1.5%)
|
1.25T
1.20T – 1.31T
+3.1% YoY
|
1.32T
1.21T – 1.42T
+6.0% YoY
|
1.40T
1.25T – 1.46T
+5.5% YoY
|
| SGA |
272.01B
est: 312.20B (-12.9%)
|
327.82B
est: 351.55B (-6.7%)
|
343.39B
est: 351.27B (-2.2%)
|
377.25B
est: 380.11B (-0.8%)
|
463.08B
est: 420.87B (+10.0%)
|
474.72B
est: 457.96B (+3.7%)
|
514.08B
est: 550.94B (-6.7%)
|
515.43B
est: 525.76B (-2.0%)
|
511.24B
est: 573.55B (-10.9%)
|
581.71B
est: 576.99B (+0.8%)
|
815.83B
est: 608.75B (+34.0%)
|
634.83B
613.55B – 658.87B
+4.3% YoY
|
671.46B
637.53B – 702.86B
+5.8% YoY
|
718.37B
713.06B – 723.68B
+7.0% YoY
|
| EPS |
14.54
est: 14.12 (+3.0%)
|
16.13
est: 15.88 (+1.6%)
|
17.81
est: 17.37 (+2.5%)
|
22.13
est: 21.96 (+0.8%)
|
26.93
est: 26.68 (+0.9%)
|
31.14
est: 30.56 (+1.9%)
|
42.28
est: 39.43 (+7.2%)
|
36.82
est: 35.60 (+3.4%)
|
31.69
est: 37.03 (-14.4%)
|
39.03
est: 37.62 (+3.8%)
|
41.36
est: 40.75 (+1.5%)
|
42.15
40.51 – 43.93
+3.4% YoY
|
44.30
40.64 – 47.67
+5.1% YoY
|
45.96
41.91 – 48.97
+3.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Budiyanto | Corporate Secretary & Director | — | male |
| David Hidayat | President Director | — | male |
| Tiur Simamora | Corporate Secretary | — | female |
| Yulius Ajie | Head of Internal Audit Unit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIDO.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
